Cobionix Raises $3M to Scale Clinical AI Robotics Platform

• Cobionix, a Canadian developer of autonomous healthcare robots, raised US $3 million to expand its modular clinical system.
• The funding, led by TitletownTech, will accelerate pilot programs in North America and the UK ahead of U.S. market entry.

Cobionix announced it has secured US $3 million in strategic funding, with TitletownTech leading the round and participation from Lions Investment and Dr. Paul McBeth. The funding will support the rollout of CODI, the company’s AI-enabled robotic platform for clinical applications.

"Medical robotics is at the intersection of several powerful technology trends, and Cobionix is harnessing that convergence in a way that has real potential to transform healthcare," said TitletownTech Managing Partner Jill Enos, in an official press release. "We're excited to support the team's vision as the company pushes the boundaries of what's possible in this space."

CODI is a configurable robotics system built to handle a range of patient-facing tasks, such as performing diagnostic ultrasound procedures. Its design supports simple tool changes and remote software updates, making it easier to switch between clinical applications without overhauling hardware.

Current pilot projects span healthcare systems in Canada, the U.S., and the UK, including partnerships with Saskatchewan Health Authority and the NHS. The funding will help advance these initiatives and support a commercial launch in the U.S. market.

🌀 Tom’s Take:

Robots like CODI help clinicians do more, from farther away. It’s about extending care, not just across tasks but across distance, without losing the human touch. Where you live shouldn’t limit the kind of medical care you get, this tech helps make sure it doesn’t.

Source: PR Newswire / Cobonix